Overview

Multiple Doses of AT-1501-A201 in Adults With ALS

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40L. Approximately 54 adults with ALS will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites. Participants will be enrolled into one of four ascending doses.

Phase:

Phase 2

Details

Lead Sponsor:

Anelixis Therapeutics, Inc.
Anelixis Therapeutics, LLC

Treatments:

Antibodies